In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Pocket Guidelines on Dyslipidaemias

ESC Pocket Guidelines

Coronary Artery Disease (Chronic)
Cardiovascular Disease in Primary Care
Rehabilitation and Sports Cardiology
Basic Science
Risk Factors and Prevention
Cardiovascular Pharmacotherapy

Chairpersons: Colin Baigent, François Mach & Alberico Catapano

Publication date: 2019

Order Pocket Guidelines


Table of contents

  • Development of the Joint Task Force guidelines
  • Total cardiovascular risk
    • Total cardiovascular risk estimation
    • Risk levels
      • Role of non-invasive cardiovascular imaging techniques on the assessment of total cardiovascular disease risk
      • Risk-based intervention strategies
  • Lipids and lipoproteins
    • The biological role of lipids and lipoproteins
  • Treatment targets and goals
  • Lifestyle modifications to improve the plasma lipid profile
    • Influence of lifestyle on total cholesterol and low-density lipoprotein cholesterol levels
    • Lifestyle recommendations to improve the plasma lipid profile
    • Dietary supplements and functional foods for the treatment of dyslipidaemias
    • Other features of a healthy diet contributing to cardiovascular disease prevention
  • Drugs for treatment of dyslipidaemias
    • Statins
    • Cholesterol absorption inhibitors
    • Bile acid sequestrants
    • PCSK9 inhibitors
    • Lomitapide
    • Mipomersen
    • Fibrates
    • n-3 fatty acids
    • Strategies to control plasma cholesterol
  • Management of dyslipidaemias in different clinical settings
    • Familial hypercholesterolaemia
    • Women
    • Older people
    • Diabetes and metabolic syndrome
    • Patients with acute coronary syndromes and patients undergoing percutaneous coronary intervention
    • Stroke
    • Heart failure and valvular diseases
    • Chronic kidney disease
    • Transplantation
    • Peripheral arterial disease
    • Other special populations at risk of atherosclerotic cardiovascular disease
  • Inflammation
  • Monitoring of lipids and enzymes in patients on lipid-lowering therapy
  • Cost-effectiveness of cardiovascular disease prevention by lipid modification
  • Strategies to encourage the adoption of healthy lifestyle changes and adherence to lipid-modifying therapies